Three-Year Outcomes of Aflibercept Treatment for Neovascular Age-Related Macular Degeneration: Evidence from a Clinical Setting

被引:34
|
作者
Eleftheriadou, Maria [1 ,2 ]
Gemenetzi, Maria [1 ,2 ]
Lukic, Marko [1 ,2 ]
Sivaprasad, Sobha [1 ,2 ]
Hykin, Philip G. [1 ,2 ]
Hamilton, Robin D. [1 ,2 ]
Rajendram, Ranjan [1 ,2 ]
Tufail, Adnan [1 ,2 ]
Patel, Praveen J. [1 ,2 ]
机构
[1] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England
[2] UCL Inst Ophthalmol, London, England
关键词
Aflibercept; AMD; Anti-VEGF; Clinical settings; Ophthalmology; Real-life outcomes; LONG-TERM OUTCOMES; CHOROIDAL NEOVASCULARIZATION; VISUAL OUTCOMES; 7-YEAR OUTCOMES; RANIBIZUMAB; MARINA; EYES; HORIZON; ANCHOR; AMD;
D O I
10.1007/s40123-018-0139-5
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
IntroductionTo report 3-year treatment outcomes with intravitreal aflibercept injections for neovascular age-related macular degeneration (nAMD) in routine clinical practice.MethodsThis was a retrospective, single-centre, non-randomized interventional case series analysis. Data from treatment-naive patients with nAMD treated between 1 October 2013 and 31 February 2014 were included in the analysis. Data including age, gender, vision acuity (VA) measured on Early Treatment of Diabetic Retinopathy Study charts (ETDRS) and injection numbers were recorded. Spectral domain optical coherence tomography (SD-OCT) data including presence or absence of macular fluid and automated central subfield macular thickness (CSMT) at year 1, 2 and 3 were also recorded.ResultsOf the 157 eyes of 148 patients treated, data from 108 eyes of 102 patients were available at 3-year follow-up. The mean (SD) age was 80.6 +/- 8.3years with a mean of 154.5 +/- 5.4weeks follow-up. The mean VA changed from 54.4 +/- 16 letters at baseline to 60.3 +/- 18.1 letters (VA gain 5.9 +/- 13.8 letter gain) at 1year, to 60.8 +/- 17.4 letters (VA gain 6.4 +/- 14.9 letters) at 2years and to 61.0 +/- 16.6 letters (VA gain 6.6 +/- 15.4 letters) at 3years. The reduction in CSMT was 77.9 +/- 101.4 mu m with absence of macular fluid in 71% of eyes. The total mean number of injections was 15.9 +/- 6.1 at year 3.Conclusion p id=Par4 The results suggest that good long-term morphological and functional treatment outcomes can be achieved using aflibercept for nAMD in a clinical setting.
引用
收藏
页码:361 / 368
页数:8
相关论文
共 50 条
  • [31] Switching from aflibercept to brolucizumab for the treatment of refractory neovascular age-related macular degeneration
    Hikaru Ota
    Jun Takeuchi
    Yuyako Nakano
    Etsuyo Horiguchi
    Yosuke Taki
    Yasuki Ito
    Hiroko Terasaki
    Koji M. Nishiguchi
    Keiko Kataoka
    Japanese Journal of Ophthalmology, 2022, 66 : 278 - 284
  • [32] Switching from aflibercept to brolucizumab for the treatment of refractory neovascular age-related macular degeneration
    Ota, Hikaru
    Takeuchi, Jun
    Nakano, Yuyako
    Horiguchi, Etsuyo
    Taki, Yosuke
    Ito, Yasuki
    Terasaki, Hiroko
    Nishiguchi, Koji M.
    Kataoka, Keiko
    JAPANESE JOURNAL OF OPHTHALMOLOGY, 2022, 66 (03) : 278 - 284
  • [33] Three-year clinical outcomes of eyes with neovascular age-related macular degeneration with baseline good visual acuity (>20/40)
    Hwang, Jonathan Cherng-En
    Chen, Jeffrey
    Nawash, Baraa
    Ong, Joshua
    Chhablani, Jay
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
  • [34] Ten-Year Treatment Outcomes of Neovascular Age-Related Macular Degeneration
    Gillies, Mark C.
    Bhandari, Sanjeeb
    Wolff, Benjamin
    Arnold, Jennifer Joan
    Essex, Rohan W.
    Young, Stephanie
    Squirrell, David M.
    Barthelmes, Daniel
    Vuong Nguyen
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
  • [35] One-Year Outcomes of Aflibercept in Recurrent or Persistent Neovascular Age-Related Macular Degeneration REPLY
    Arcinue, Cheryl A.
    Ma, Feiyan
    Barteselli, Giulio
    Sharpsten, Lucie
    Gomez, Maria Laura
    Freeman, William R.
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2015, 159 (05) : 997 - 997
  • [36] A Trinity regimen with aflibercept for treatment-naive neovascular age-related macular degeneration: 2-year outcomes
    Wakuta, Makiko
    Nomi, Nanami
    Ogata, Tadahiko
    Ota, Manami
    Yamashiro, Chiemi
    Hatano, Makoto
    Yanai, Ryoji
    Tokuda, Kazuhiro
    Kimura, Kazuhiro
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2020, 258 (08) : 1663 - 1670
  • [37] Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-related Macular Degeneration Patients: 3-Year Outcomes
    Wijeyakumar, Wijeyanthy
    Zhu, Meidong
    Chang, Andrew Alexander
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
  • [38] Three-Year Outcomes of Wet Age-Related Macular Degeneration Treatment in Polish Therapeutic Programs
    Figurska, Malgorzata
    Rekas, Marek
    MEDICINA-LITHUANIA, 2022, 58 (01):
  • [39] Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-related Macular Degeneration
    Chang, Andrew A.
    Li, Haitao
    Broadhead, Geoffrey K.
    Hong, Thomas
    Schlub, Timothy E.
    Wijeyakumar, Wijeyanthy
    Zhu, Meidong
    OPHTHALMOLOGY, 2014, 121 (01) : 188 - 192
  • [40] Aflibercept in the Treatment of Neovascular Age-Related Macular Degeneration in Previously Treated Patients
    Hall, Laura B.
    Zebardast, Nazlee
    Huang, John J.
    Adelman, Ron A.
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2014, 30 (04) : 346 - 352